TAKEDA PHARMACEUTICAL CO LTD

TKPHF

$45.57B

Large Cap

NASDAQBiotechnology🇺🇸North America47.5K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 19, 2026

11d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

8 upcoming, 1 past

Phase 2Next

TAK-360 Phase 2 Results Expected

Feb 19, 2026TAK-36040

Primary completion for TAK-360 trial (NCT06812078) in Idiopathic Hypersomnia

Source

Phase 2

Dazostinag Phase 2 Results Expected

Mar 31, 2026Dazostinag248

Primary completion for Dazostinag trial (NCT04420884) in Solid Neoplasms

Source

⭐Phase 3

Vedolizumab IV Phase 3 Results Expected

May 22, 2026Vedolizumab IV120

Primary completion for Vedolizumab IV trial (NCT04779320) in Crohn's Disease (CD)

Source

⭐Phase 3

Zasocitinib Phase 3 Results Expected

Jun 5, 2026Zasocitinib606

Primary completion for Zasocitinib trial (NCT06973291) in Plaque Psoriasis

Source

⭐Phase 3

Deucravacitinib Phase 3 Results Expected

Jun 5, 2026Deucravacitinib606

Primary completion for Deucravacitinib trial (NCT06973291) in Plaque Psoriasis

Source

⭐Phase 3

Tetravalent Dengue Vaccine (TDV) Phase 3 Results Expected

Aug 30, 2026Tetravalent Dengue Vaccine (TDV)496

Primary completion for Tetravalent Dengue Vaccine (TDV) trial (NCT07047521) in Dengue Fever

Source

Phase 2

TAK-279 Phase 2 Results Expected

Sep 30, 2026TAK-279207

Primary completion for TAK-279 trial (NCT06254950) in Ulcerative Colitis

Source

Phase 2

TAK-788 Phase 2 Results Expected

Oct 31, 2026TAK-788334

Primary completion for TAK-788 trial (NCT02716116) in Carcinoma, Non-Small-Cell Lung

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Leuprorelin SR

Phase 3

Prostatic Neoplasms, Locally Advanced

Deucravacitinib

Phase 3

Plaque Psoriasis

Epoetin

Phase 3

Chronic Kidney Disease

Allopurinol

Phase 3

Gout

Glimepiride

Phase 3

Diabetes Mellitus

von Willebrand factor (Recombinant)

Phase 3

Von Willebrand Disease

TDV

Phase 3

Healthy

Azilsartan medoxomil and olmesartan

Phase 3

Hypertension

Vedolizumab

Phase 3

Ulcerative Colitis

Peginesatide

Phase 3

Anemia

Pioglitazone and Glimepiride

Phase 3

Diabetes Mellitus

Teduglutide

Phase 3

Short Bowel Syndrome

TAK-861

Phase 3

Narcolepsy Type 1

TVP-1012

Phase 3

Parkinson's Disease

Actovegin

Phase 3

Peripheral Arterial Diseases

Vedolizumab IV

Phase 3

Crohn's Disease

TachoSil®

Phase 3

Hemorrhage

Pantoprazole

Phase 3

Gastroesophageal Reflux

Tetravalent Dengue Vaccine (TDV)

Phase 3

Dengue Fever

TAK-771

Phase 3

Primary Immunodeficiency Diseases (PID)

Surgicel® Original

Phase 3

Bleeding

Vedolizumab SC

Phase 3

Ulcerative Colitis

TAP-144-SR(6M)

Phase 3

Prostate Cancer

Fasiglifam

Phase 3

Diabetes Mellitus, Type 2

Zasocitinib

Phase 3

Plaque Psoriasis

Alogliptin Benzoate

Phase 3

Diabetes Mellitus, Type 2

Febuxostat IR

Phase 3

Gout

TVP-1012 1mg

Phase 3

Parkinson's Disease

Metformin HCl

Phase 3

Diabetes Mellitus

TAK-667

Phase 3

Hereditary Angioedema

SYR-472

Phase 3

Diabetes Mellitus

Dexlansoprazole MR

Phase 3

Esophagitis, Reflux

Azilsartan medoxomil

Phase 3

Hypertension

Ramelteon

Phase 3

Sleep Disorder

Azilsartan medoxomil and hydrochlorothiazide

Phase 3

Essential Hypertension

Vortioxetine

Phase 3

Depressive Disorder, Major

TAK-583

Phase 3

Neuralgia, Postherpetic

Darvadstrocel

Phase 3

Crohn's Disease

Soticlestat

Phase 3

Lennox Gastaut Syndrome (LGS)

Omega-3-acid ethyl esters 90 (TAK-085)

Phase 3

Hypertriglyceridemia

Maribavir

Phase 3

Cytomegalovirus (CMV)

Idursulfase-IT

Phase 3

Hunter Syndrome

Alogliptin and pioglitazone

Phase 3

Diabetes Mellitus

TAK-536CCB

Phase 3

Grade I or II Essential Hypertension

TAK-438

Phase 3

Gastric Ulcers

Lansoprazole and naproxen and aspirin

Phase 3

Osteoarthritis

Azilsartan medoxomil and chlorthalidone

Phase 3

Hypertension

TAK-881

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

Phase 3

Colorectal Cancer

Pioglitazone and Metformin

Phase 3

Diabetes Mellitus

Lanadelumab

Phase 3

Angioedema

Lubiprostone

Phase 3

Chronic Idiopathic Constipation

Active Comparator

Phase 3

Psoriatic Arthritis

Alogliptin

Phase 3

Diabetes Mellitus

Alogliptin and voglibose

Phase 3

Type 2 Diabetes Mellitus

Dexlansoprazole MR QD

Phase 3

Gastroesophageal Reflux

Ixazomib

Phase 2

Multiple Myeloma

Febuxostat

Phase 2

Renal Impairment

TAK-861 2 mg

Phase 2

Narcolepsy Type 2

Pioglitazone and azilsartan

Phase 2

Diabetes Mellitus

TAK-715 and methotrexate

Phase 2

Arthritis, Rheumatoid

Ruxolitinib

Phase 2

Myelofibrosis

TAK-385

Phase 2

Uterine Fibroids

TAK-272

Phase 2

Type 2 Diabetes Mellitus and Microalbuminuria

TD-8954

Phase 2

Enteral Feeding Intolerance

TAK-360

Phase 2

Idiopathic Hypersomnia

GI.1/GII.4 (15/15)

Phase 2

Norovirus

Niraparib

Phase 2

Ovarian Cancer

TAK-411

Phase 2

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

TAK-101

Phase 2

Celiac Disease

Dazostinag

Phase 2

Solid Neoplasms

TAK-951

Phase 2

Postoperative Nausea and Vomiting (PONV)

NDI-034858 study drug

Phase 2

Moderate to Severe Plaque Psoriasis

TAK-662

Phase 2

Congenital Protein C Deficiency

Dexlansoprazole

Phase 2

Erosive Esophagitis

TAK-919

Phase 2

Coronavirus Disease (COVID-19)

Namilumab

Phase 2

Rheumatoid Arthritis

TAK-788

Phase 2

Carcinoma, Non-Small-Cell Lung

TAK-850

Phase 2

Influenza Infection

GDX012

Phase 2

Leukemia

Pioglitazone and ramipril

Phase 2

Inflammation

Pioglitazone and atorvastatin

Phase 2

Cardiovascular Diseases

TAK-188

Phase 2

Advanced or Metastatic Solid Tumors

Levothyroxine sodium new formulation

Phase 2

Hypothyroidism

TAK-935

Phase 2

Developmental and/or Epileptic Encephalopathies

Voglibose

Phase 2

Type 2 Diabetes Mellitus

Drug Name	Phase	Indication	Designations
Leuprorelin SR	Phase 3	Prostatic Neoplasms, Locally Advanced	-
Deucravacitinib	Phase 3	Plaque Psoriasis	-
Epoetin	Phase 3	Chronic Kidney Disease	-
Allopurinol	Phase 3	Gout	-
Glimepiride	Phase 3	Diabetes Mellitus	-
von Willebrand factor (Recombinant)	Phase 3	Von Willebrand Disease	-
TDV	Phase 3	Healthy	-
Azilsartan medoxomil and olmesartan	Phase 3	Hypertension	-
Vedolizumab	Phase 3	Ulcerative Colitis	-
Peginesatide	Phase 3	Anemia	-
Pioglitazone and Glimepiride	Phase 3	Diabetes Mellitus	-
Teduglutide	Phase 3	Short Bowel Syndrome	-
TAK-861	Phase 3	Narcolepsy Type 1	-
TVP-1012	Phase 3	Parkinson's Disease	-
Actovegin	Phase 3	Peripheral Arterial Diseases	-
Vedolizumab IV	Phase 3	Crohn's Disease	-
TachoSil®	Phase 3	Hemorrhage	-
Pantoprazole	Phase 3	Gastroesophageal Reflux	-
Tetravalent Dengue Vaccine (TDV)	Phase 3	Dengue Fever	-
TAK-771	Phase 3	Primary Immunodeficiency Diseases (PID)	-
Surgicel® Original	Phase 3	Bleeding	-
Vedolizumab SC	Phase 3	Ulcerative Colitis	-
TAP-144-SR(6M)	Phase 3	Prostate Cancer	-
Fasiglifam	Phase 3	Diabetes Mellitus, Type 2	-
Zasocitinib	Phase 3	Plaque Psoriasis	-
Alogliptin Benzoate	Phase 3	Diabetes Mellitus, Type 2	-
Febuxostat IR	Phase 3	Gout	-
TVP-1012 1mg	Phase 3	Parkinson's Disease	-
Metformin HCl	Phase 3	Diabetes Mellitus	-
TAK-667	Phase 3	Hereditary Angioedema	-
SYR-472	Phase 3	Diabetes Mellitus	-
Dexlansoprazole MR	Phase 3	Esophagitis, Reflux	-
Azilsartan medoxomil	Phase 3	Hypertension	-
Ramelteon	Phase 3	Sleep Disorder	-
Azilsartan medoxomil and hydrochlorothiazide	Phase 3	Essential Hypertension	-
Vortioxetine	Phase 3	Depressive Disorder, Major	-
TAK-583	Phase 3	Neuralgia, Postherpetic	-
Darvadstrocel	Phase 3	Crohn's Disease	-
Soticlestat	Phase 3	Lennox Gastaut Syndrome (LGS)	-
Omega-3-acid ethyl esters 90 (TAK-085)	Phase 3	Hypertriglyceridemia	-
Maribavir	Phase 3	Cytomegalovirus (CMV)	-
Idursulfase-IT	Phase 3	Hunter Syndrome	-
Alogliptin and pioglitazone	Phase 3	Diabetes Mellitus	-
TAK-536CCB	Phase 3	Grade I or II Essential Hypertension	-
TAK-438	Phase 3	Gastric Ulcers	-
Lansoprazole and naproxen and aspirin	Phase 3	Osteoarthritis	-
Azilsartan medoxomil and chlorthalidone	Phase 3	Hypertension	-
TAK-881	Phase 3	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	-
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab	Phase 3	Colorectal Cancer	-
Pioglitazone and Metformin	Phase 3	Diabetes Mellitus	-
Lanadelumab	Phase 3	Angioedema	-
Lubiprostone	Phase 3	Chronic Idiopathic Constipation	-
Active Comparator	Phase 3	Psoriatic Arthritis	-
Alogliptin	Phase 3	Diabetes Mellitus	-
Alogliptin and voglibose	Phase 3	Type 2 Diabetes Mellitus	-
Dexlansoprazole MR QD	Phase 3	Gastroesophageal Reflux	-
Ixazomib	Phase 2	Multiple Myeloma	-
Febuxostat	Phase 2	Renal Impairment	-
TAK-861 2 mg	Phase 2	Narcolepsy Type 2	-
Pioglitazone and azilsartan	Phase 2	Diabetes Mellitus	-
TAK-715 and methotrexate	Phase 2	Arthritis, Rheumatoid	-
Ruxolitinib	Phase 2	Myelofibrosis	-
TAK-385	Phase 2	Uterine Fibroids	-
TAK-272	Phase 2	Type 2 Diabetes Mellitus and Microalbuminuria	-
TD-8954	Phase 2	Enteral Feeding Intolerance	-
TAK-360	Phase 2	Idiopathic Hypersomnia	-
GI.1/GII.4 (15/15)	Phase 2	Norovirus	-
Niraparib	Phase 2	Ovarian Cancer	-
TAK-411	Phase 2	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	-
TAK-101	Phase 2	Celiac Disease	-
Dazostinag	Phase 2	Solid Neoplasms	-
TAK-951	Phase 2	Postoperative Nausea and Vomiting (PONV)	-
NDI-034858 study drug	Phase 2	Moderate to Severe Plaque Psoriasis	-
TAK-662	Phase 2	Congenital Protein C Deficiency	-
Dexlansoprazole	Phase 2	Erosive Esophagitis	-
TAK-919	Phase 2	Coronavirus Disease (COVID-19)	-
Namilumab	Phase 2	Rheumatoid Arthritis	-
TAK-788	Phase 2	Carcinoma, Non-Small-Cell Lung	-
TAK-850	Phase 2	Influenza Infection	-
GDX012	Phase 2	Leukemia	-
Pioglitazone and ramipril	Phase 2	Inflammation	-
Pioglitazone and atorvastatin	Phase 2	Cardiovascular Diseases	-
TAK-188	Phase 2	Advanced or Metastatic Solid Tumors	-
Levothyroxine sodium new formulation	Phase 2	Hypothyroidism	-
TAK-935	Phase 2	Developmental and/or Epileptic Encephalopathies	-
Voglibose	Phase 2	Type 2 Diabetes Mellitus	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

TKPHF News